BNP Paribas Financial Markets Sells 84,424 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)

BNP Paribas Financial Markets reduced its position in Surgery Partners, Inc. (NASDAQ:SGRY) by 83.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 16,616 shares of the company’s stock after selling 84,424 shares during the period. BNP Paribas Financial Markets’ holdings in Surgery Partners were worth $536,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SGRY. Quarry LP boosted its stake in Surgery Partners by 133.1% in the 2nd quarter. Quarry LP now owns 3,082 shares of the company’s stock worth $73,000 after purchasing an additional 1,760 shares during the period. KBC Group NV increased its stake in shares of Surgery Partners by 31.8% in the third quarter. KBC Group NV now owns 2,385 shares of the company’s stock worth $77,000 after buying an additional 576 shares during the period. Creative Planning bought a new stake in shares of Surgery Partners in the third quarter worth about $258,000. Versor Investments LP purchased a new position in Surgery Partners during the 3rd quarter valued at about $271,000. Finally, MeadowBrook Investment Advisors LLC lifted its stake in Surgery Partners by 15.9% in the second quarter. MeadowBrook Investment Advisors LLC now owns 12,320 shares of the company’s stock worth $293,000 after acquiring an additional 1,690 shares during the period.

Surgery Partners Stock Performance

SGRY stock opened at $20.36 on Friday. Surgery Partners, Inc. has a 1-year low of $19.90 and a 1-year high of $36.92. The company has a market capitalization of $2.59 billion, a P/E ratio of -42.42, a PEG ratio of 17.95 and a beta of 2.58. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. The business has a 50-day moving average price of $26.93 and a 200 day moving average price of $27.95.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). The firm had revenue of $770.40 million for the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. Surgery Partners’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.15 EPS. As a group, equities research analysts forecast that Surgery Partners, Inc. will post 0.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SGRY. KeyCorp assumed coverage on Surgery Partners in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. UBS Group initiated coverage on Surgery Partners in a research report on Monday, October 14th. They issued a “buy” rating and a $38.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $43.00 target price on shares of Surgery Partners in a research note on Friday, October 4th. Macquarie reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Surgery Partners in a research note on Tuesday, November 19th. Finally, Benchmark reissued a “buy” rating and issued a $50.00 target price on shares of Surgery Partners in a report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.38.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.